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Abstract: Engineering new bone tissue with cells and a
synthetic extracellular matrix (scaffolding) represents a new
approach for the regeneration of mineralized tissues com-
pared with the transplantation of bone (autografts or allo-
grafts). In the present work, highly porous poly(L-lactic acid)
(PLLA) and PLLA/hydroxyapatite (HAP) composite scaf-
folds were prepared with a thermally induced phase sepa-
ration technique. The scaffolds were seeded with osteoblas-
tic cells and cultured in vitro. In the pure PLLA scaffolds, the
osteoblasts attached primarily on the outer surface of the
polymer. In contrast, the osteoblasts penetrated deep into
the PLLA/HAP scaffolds and were uniformly distributed.
The osteoblast survival percentage in the PLLA/HAP scaf-
folds was superior to that in the PLLA scaffolds. The osteo-
blasts proliferated in both types of the scaffolds, but the cell
number was always higher in the PLLA/HAP composite
scaffolds during 6 weeks of in vitro cultivation. Bone-specific
markers (mRNAs encoding bone sialoprotein and osteocal-
cin) were expressed more abundantly in the PLLA/HAP
composite scaffolds than in the PLLA scaffolds. The new
tissue increased continuously in the PLLA/HAP composite
scaffolds, whereas new tissue formed only near the surface
of pure PLLA scaffolds. These results demonstrate that HAP
imparts osteoconductivity and the highly porous PLLA/
HAP composite scaffolds are superior to pure PLLA scaf-
folds for bone tissue engineering. © 2000 John Wiley & Sons,
Inc. J Biomed Mater Res 54: 284–293, 2001
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INTRODUCTION
Bone fractures and damage result in more than 1.3
million surgical procedures each year in the United
States.1 Approximately 500,000 vertebral fractures oc-
cur annually in the United States, along with 250,000
proximal femur and 200,000 distal radius fractures.2 In
addition, over 120,000 total hip arthroplasties are per-
formed there each year.3,4 In dentistry, plastic and re-
constructive surgeries are performed daily for cranio-
facial bone reconstruction and replacement.5 Bone
grafting is increasing and the failure rate is unaccept-
able.6,7 In patients who are managed with various
bone grafts, a failure rate ranging from 16% to 50% is
reported.6,8,9 The failure rate of autografts is at the
lower end of the spectrum,10 but the need for second
site of surgery, limited supply, inadequate size and
shape, and the morbidity associated with donor site
are all major concerns.11
Engineering osseous tissue with cells and a syn-
thetic extracellular matrix is a new approach com-
pared to transplantation of harvested tissues. In this
approach, a highly porous scaffold serves as the
growth substrate for osteoblasts or osteoprogenitor
cells. This scaffold should allow nutrients and metabo-
lites to permeate, should be conducive to vasculariza-
tion, and should serve as a guide for cell growth and
new bone tissue formation in three dimensions. Bio-
degradable polymers such as poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and poly(lactic acid-co-
glycolic acid) (PLGA) are widely used as scaffolding
materials for a variety of tissue engineering applica-
tions because they degrade and resorb after fulfilling
the template function so that there will be no long-
term foreign-body reaction and complications.1,12–15
Poly(lactic acid-co-glycolic acids) have been studied
as scaffolding materials for bone tissue engineer-
ing.16,17 A salt-leaching technique has been used
to generate porous foams of degradable poly-
mers.12,14,18,19 PLGA (75:25) was processed into po-
rous foam using this technique and cultured with stro-
mal osteoblastic cells by Ishaug et al.17 One of the
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limitations was that the new tissue matrix was formed
only at the surface layer of the foam (<240 mm) with
only a minimum number of cells located in the center.
The scaffolding materials for bone tissue engineer-
ing should be osteoconductive so that osteoblasts and
osteoprogenitor cells can adhere, migrate on the scaf-
folds, differentiate, and synthesize new bone matrix.
With this approach, we can potentially use the pa-
tient’s own cells so that immunosuppression is not
needed. The new tissue should also have the potential
to grow and remodel, which is especially important
for pediatric patients. We hypothesize that hydroxy-
apatite can improve osteoconductivity of biodegrad-
able polymer scaffolds; and as a mineral existing in
natural bone, it will be a site for new bone deposition
and therefore be integrated within new bone after the
polymer degrades.20
Previously, a composite scaffold of PLGA (50:50)
and hydroxyapatite (HAP) was fabricated with the
salt-leaching technique by Laurencin and cowork-
ers.21,22 In a 21-day primary osteoblast culture, the
HAP-containing matrix showed some promising fea-
tures in cell attachment and differentiated function.
However, the matrix porosity was quite low (based on
the mixture used to make the matrix: PLGA:HAP:
NaCl = 1:1:1), which might not be ideal for long-term
cell survival, proliferation, and tissue formation owing
to mass transport limitations. We used a novel solid–
liquid phase separation technique to create highly po-
rous (as high as 95% porosity) poly(a-hydroxyl ac-
ids)/HAP composite scaffolds.20 It was demonstrated
that the porosity, pore size, and pore morphology of
these composite foams could be controlled by the
polymer concentration, chemical structure of the poly-
mer, HAP content, phase-separation temperature, and
solvent used.20 The high porosity was expected to bet-
ter satisfy the cell penetration and mass transport re-
quirements (for nutrient, metabolites, and soluble sig-
nals) for tissue engineering.13,14,23 Therefore, highly
porous biodegradable polymer/HAP composite scaf-




Poly(L-lactic acid) with an inherent viscosity of approxi-
mately 1.6 was purchased from Boehringer Ingelheim (In-
gelheim, Germany). The polymer was used without further
purification. Dioxane and HAP [Ca10(PO4)6(OH)2] were ob-
tained from Aldrich Chemical Company (Milwaukee, WI).
Fetal bovine serum, a-minimum essential medium (a-
MEM), ascorbic acid-free a-MEM (Formula 94-5049EL),
penicillin–streptomycin, Dulbecco’s phosphate-buffered sa-
line (PBS), trypsin-EDTA, and sodium bicarbonate were
purchased from Gibco BRL Products, Life Technologies
(Grand Island, NY). Ascorbic acid was purchased from
Fisher Scientific (Pittsburgh, PA). Neutral-buffered formalin,
Trypan blue, and dimethylsulfoxide (DMSO) were pur-
chased from Sigma Chemical Co. (St. Louis, MO). Ethylene
oxide was purchased from H. W. Anderson Products
(Chapel Hill, NC).
Polymer and polymer/HAP scaffolds
The preparation and morphology of PLLA and PLLA/
HAP scaffolds have been reported in detail earlier.20 Briefly,
PLLA was dissolved in dioxane to make a 5% (w/v) solu-
tion. To prepare the composite scaffolds, hydroxyapatite
powder (platelets ranging from 10 to 100 mm in size) was
added into the prepared PLLA solution. A solid-liquid
phase separation technique and a subsequent solvent subli-
mation process were used to generate the highly porous
PLLA and PLLA/HAP composite scaffolds. The PLLA/
dioxane solution and PLLA/HAP/dioxane mixture were
cooled to −18°C to induce solid–liquid phase separation. The
phase-separated samples were dried under vacuum (0.5
mmHg) at between −5°C and −10°C for 7 days to remove the
solvent completely.20
The density and porosity of the porous PLLA and PLLA/
HAP composite scaffolds were determined with a liquid dis-
placement method as reported in detail earlier.20,24 Ethanol
was used as the displacing liquid because it penetrated eas-
ily into the pores and did not induce shrinkage or swelling.
With this method, the total pore volume, polymer or poly-
mer/HAP skeleton volume, and the overall scaffold volume
were determined to calculate the density and porosity.20,24
The compressive mechanical properties of the foams were
characterized with an Instron mechanical tester (Model 4502;
Instron Co., Canton, MA). Circular disk specimens (16 mm
in diameter, and 3 mm thick) were tested with a crosshead
speed of 0.5 mm/min. Five or more specimens were tested
for each sample, and the averages and standard deviations
were calculated. A two-tailed Student t test was performed
to determine the statistical significance (p < .05) of the dif-
ferences between samples.
The porous morphologies of the PLLA and PLLA/HAP
composite foams were examined with scanning electron mi-
croscopy (SEM; S-3200N, Hitachi, Japan) at 15 kV. The speci-
mens were cut with a razor blade after being frozen in liquid
nitrogen for 5 min. The cut specimens were then coated with
gold using a sputter coater (Desk-II, Denton Vacuum Inc.)
for 200 s. The gas pressure was <50 mtorr and the current
was approximately 40 mA.
Osteoblast passage, seeding, and culture
The thawed MC3T3-E1 osteoblasts (clone 4)25 were cul-
tured in a supplemented ascorbic acid-free a-MEM [For-
mula 94-5049EL; 10% fetal bovine serum (FBS), 50 U/mL
penicillin, and 50 mg/mL streptomycin] in a humidified in-
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cubator at 37°C with a CO2/air ratio of 5:95. The medium
was changed every other day. The cells of passages 3 and 4
were seeded on to the PLLA and PLLA/HAP scaffolds. The
viability of the cells before seeding was higher than 90%
determined with the Trypan blue exclusion assay.
The porous PLLA and PLLA/HAP disks with a diameter
of 10 mm and thickness of 1.5 mm were prepared. These
scaffolds were assembled on the bottoms of custom-made
12-well Teflon culture plates with a well diameter of 10 mm.
The scaffold-containing culture plates were sterilized with
ethylene oxide. The sterilized PLLA and PLLA/HAP scaf-
folds (assembled in the wells) were soaked in ethanol for 30
min and then exchanged with phosphate-buffered saline
three times (30 min each). The scaffolds were then washed
with a complete medium (a-MEM, 10% FBS, 50 U/mL peni-
cillin, 50 mg/mL streptomycin, and an additional 50 mg/L
of L-ascorbic acid) two times (2 h each). The medium was
then decanted and 2 million cells (suspended in 0.5 mL of
the complete medium) were seeded on each scaffold. The
cell-scaffold constructs (in the Teflon plates) were cultured
on an orbital shaker (Model 3520; Lab-Line Instruments,
Melrose Park, IL) at 75 rpm in a humidified incubator with
a CO2/air ratio of 5:95. The medium was changed two times
a day (0.5 mL) for 2 days.
After the 48-h cell seeding, the polymer–osteoblast con-
structs were removed from the Teflon plates and transferred
into six-well tissue culture plates. The constructs were cul-
tured with the complete medium on the orbital shaker at 75
rpm in the humidified incubator. Four-milliliter medium
was used for each construct and the medium was changed
every other day.
Histology
Osteoblast–PLLA and osteoblast–PLLA/HAP constructs
were cultured in vitro for varying time intervals (the culture
time was calculated from the day of cell seeding), and then
fixed in 10% neutral-buffered formalin. Paraffin-embedded
disk specimens were cut into 5-mm-thick cross sections and
stained with hematoxylin and eosin, or von Kossa’s silver
nitrate.
RNA extraction and Northern blot analysis
To obtain as much RNA as possible from the osteoblast–
PLLA and osteoblast–PLLA/HAP constructs that were me-
chanically strong, samples were homogenized with a Poly-
tron homogenizor (Brinkmann Easycare Generator; POLY-
TRON-Aggregate, Switzerland) for 30 s at top speed (VI) for
three times before preparing RNA according to the method
of Chomczynski and Sacchi.26 Aliquots of total RNA were
fractionated on 1.0% agarose-formaldehyde gels and blotted
onto nitrocellulose paper as described by Thomas.27 The
mouse cDNA probes used for hybridization were obtained
from the following sources: osteocalcin from Dr. John
Wozney (Genetics Institute, Boston, MA)28 and bone sia-
loprotein from Dr. Marion Young (NIDR, Bethesda, MD).29
All cDNA inserts were excised from plasmid DNA with the
appropriate restriction enzymes and purified by agarose gel
electrophoresis before labeling with a-[32P]-dCTP using a
random primer kit (Boehringer-Mannheim, Indianapolis,
IN). Hybridizations were performed as previously described
using a Bellco Autoblot hybridization oven30 and quantita-
tively scanned using a Packard A2024 InstantImager. All
values were normalized for RNA loading by probing blots
with cDNA to 18S rRNA.31 At least three repeats were ana-
lyzed for each sample, and representative results are re-
ported.
DNA assay
Osteoblast adhesion and proliferation on the scaffolds
were quantified with a previously described DNA assay.25,32
To remove the large amounts of HAP that may interfere
with the assay, the osteoblast–PLLA/HAP constructs were
homogenized as described above and precipitated in 0.4 N
perchloric acid (PCA). The DNA assay was then performed
using the method of Schneider.33 Two to four repeats were
analyzed for each sample, and the averages and standard
deviations were plotted.
RESULTS
The PLLA and PLLA/HAP porous scaffolds were
prepared with a solid–liquid phase separation tech-
nique similar to that detailed previously.20 Foams pre-
pared from a 5% PLLA/dioxane solution and a sus-
pension of HAP in 5% PLLA/dioxane (HAP:PLLA =
1:1) were interconnected with pore size ranging from
tens to hundreds of micrometers (Fig. 1). The mor-
phology of the PLLA foam was different from that of
the PLLA/HAP foam. The pores of PLLA foam were
relatively regular in shape, whereas the pores of the
PLLA/HAP foam were irregular in shape. These ob-
servations were consistent with those reported ear-
lier.20 The porosity of the PLLA/HAP composite foam
(89.2%) was slightly lower than that of the pure PLLA
foam (92.7%). The mechanical properties of the PLLA/
HAP foam were improved over those of the pure
PLLA foam (Table I). Both compressive modulus and
compressive yield strength of the PLLA/HAP com-
posite foam were significantly higher than those of the
pure PLLA foam (p < .05).
Osteoblasts were more uniformly distributed in the
PLLA/HAP scaffolds than in pure PLLA scaffolds
(Fig. 2). For both PLLA and PLLA/HAP scaffolds, os-
teoblasts were more abundant in the surface regions
than in the central regions 1 week after cell seeding.
However, repeated histological observations showed
that a large amount of osteoblasts penetrated deep
into and relatively uniformly distributed in the central
area of the PLLA/HAP scaffolds, whereas there were
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only scattered osteoblasts in the central area of the
pure PLLA scaffolds.
The DNA content of the osteoblast–scaffold con-
structs was measured to quantify the osteoblast adhe-
sion and proliferation on the PLLA and PLLA/HAP
scaffolds. Control experiments showed that neither
scaffold interfered with the DNA assay. The cell num-
bers adhered on the two types of scaffolds after 5 h of
cell seeding were statistically identical (Table II). One
week after cell seeding, the cell numbers on the
PLLA/HAP scaffolds were significantly higher than
those on the PLLA scaffolds (Fig. 3). The average cell
number on the PLLA/HAP scaffolds was slightly
higher than that adhered after the initial 5 h of cell
seeding (DNA: 28.5 mg vs. 25.8 mg), whereas the cell
number on the PLLA scaffolds was significantly lower
than that adhered after the initial 5 h of cell seeding
(DNA: 9.9 mg vs. 25.6 mg). It was obvious that the cell
survival rate (and growth) during the first week of
culture in the PLLA/HAP scaffolds was much higher
than that in the pure PLLA scaffolds. The osteoblasts
proliferated over the in vitro cultivation time in both
types of scaffolds during the 6-week in vitro cultiva-
tion. The cell number in the PLLA/HAP scaffolds was
always higher than that in the PLLA scaffolds during
the 6 weeks of culture (Fig. 3).
The cell distribution and morphogenesis were visu-
alized by histologic analysis (Fig. 4). In the central
areas of the PLLA scaffolds, the cell number and tissue
mass did not change significantly in the first 4 weeks,
Figure 1. Scanning electron micrographs of PLLA and PLLA/HAP (PLLA/HAP: 50:50) foams prepared from a 5% (w/v)
PLLA/dioxane solution: (a) PLLA, ×100; (b) PLLA, ×500; (c) PLLA/HAP, ×100; (d) PLLA/HAP, ×500.
TABLE I
Compressive Mechanical Properties of PLLA and
PLLA/HAP Composite Scaffolds Made from 5%
PLLA/Dioxane Solution
Modulus (MPa) Yield Strength (MPa)
PLLA 6.42 ± 1.44 0.32 ± 0.04
PLLA/HAP (1:1) 10.87 ± 3.20 0.39 ± 0.01
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but some small tissue domains formed after 8 weeks of
in vitro culture. In contrast, cell number and new tissue
mass seemed to increase continuously in the PLLA/
HAP scaffolds. After 8 weeks of in vitro cultivation, the
new tissue became nearly continuous (Figs. 4 and 5).
However, the tissue mass was slightly denser in the
areas closer to the surfaces of the osteoblast–PLLA/
HAP constructs than in the very central areas. Some
ossification was also observed (dark areas) but the
relative cellular contribution to this process could not
be evaluated accurately because of interference from
the HAP particles incorporated into the scaffolds.
More detailed experiments are needed to study the
ossification process. In vivo implantation experiments
are also being conducted to enhance ossification with
the desired vascularization.
Figure 2. Osteoblastic cell distribution in highly porous PLLA and PLLA/HAP composite scaffolds 1 week after cell seeding
(von Kossa’s silver nitrate staining; original magnification ×100): (a) the surface area of an osteoblast–PLLA construct; (b) the
center of an osteoblast–PLLA construct; (c) the surface area of an osteoblast–PLLA/HAP construct; and (d) the center of an
osteoblast–PLLA/HAP construct.
TABLE II
Adhesion of MC3T3-E1 Cells onto PLLA and PLLA/HAP
Composite Scaffolds after 5 h Cell Seeding
DNA (mg)
PLLA 25.63 ± 1.57
PLLA/HAP (1:1) 25.80 ± 0.75
Figure 3. Osteoblast proliferation in the PLLA and PLLA/
HAP scaffolds versus in vitro cultivation time; 2 × 106
MC3T3-E1 subclone 4 cells were seeded into each scaffold
and fed every other day until harvest. DNA contents at each
time point were determined as described in Materials and
Methods.
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The osteoblasts in the PLLA/HAP scaffolds showed
a highly differentiated phenotype. Bone specific gene
expression was analyzed in both osteoblast–PLLA and
osteoblast–PLLA/HAP constructs. MC3T3-E1 cells,
like other osteoblast cell lines, are phenotypically het-
erogeneous; i.e., only a fraction of the cells exhibit os-
teoblast characteristics. To obtain a highly responsive
cell population, MC3T3-E1 cells were subcloned as
previously described.25 Highly responsive clone 4
cells were used in the current investigation. Northern
blots were probed for mRNAs encoding bone sia-
loprotein (BSP) and osteocalcin (OCN), two well-
characterized osteoblast-specific gene products, in the
osteoblast-scaffold constructs (Fig. 6). The values were
normalized for RNA loading by probing blots with
cDNA to 18S rRNA (Fig. 7). The mRNAs of both BSP
Figure 4. Osteoblast–PLLA and osteoblast–PLLA/HAP constructs cultured in vitro for varying times (von Kossa’s silver
nitrate staining, original magnification ×100): (a) PLLA, 2 weeks; (b) PLLA/HAP, 2 weeks; (c) PLLA, 4 weeks; (d) PLLA/HAP,
4 weeks; (e) PLLA, 8 weeks; (f) PLLA/HAP, 8 weeks.
289ENGINEERING BONE ON PLLA/HAP
and OCN increased with cultivation time, which dem-
onstrated that the scaffolding architecture was suit-
able for osteoblast differentiation. The mRNA levels
for both BSP and OCN were higher in the osteoblast–
PLLA/HAP constructs than in the osteoblast–PLLA
constructs, which showed the advantages of the osteo-
conductivity imparted by HAP. The differences in the
expression levels of bone-specific markers were more
significant at the later stage of the culture. The drop in
the marker expression levels at week 6 in the PLLA
scaffolds might be caused by the worse mass transport
limitations owing to the surface tissue growth in the
PLLA scaffolds as opposed to the more homogeneous
three-dimensional tissue formation in the PLLA/HAP
scaffolds.
DISCUSSION
Bone is the primary constituent of the human skel-
eton. Because of its rigidity and strength, bone is the
framework on which soft tissues are attached and act
against to produce movement. Its four main functions
are to provide mechanical support (e.g., ribs), to per-
mit locomotion (e.g., long bones), to provide protec-
tion (e.g., skull), and to provide a reservoir of calcium,
phosphorous, and other ions (bone contains about
99% of the body’s calcium) to control and balance the
ionic content in body fluids (homeostasis). Bone ma-
trix is composed of an organic portion and an inor-
ganic (calcified) portion. The inorganic portion is com-
posed of calcium, phosphate, bicarbonate, citrate,
magnesium, potassium, and sodium. This portion rep-
resents 50% of the dry weight of bone, and consists
primarily of HAP crystals, which have the composi-
tion Ca10(PO4)6(OH)2. The organic portion consists
primarily of type I collagen (95%) and small amount of
ground substance that contains glycoproteins, proteo-
glycans, and glycosaminoglycans. Some of these mol-
ecules have been shown to bind calcium and may play
a role in matrix calcification. Among the noncollag-
enous glycoproteins are osteocalcin (OCN), osteopon-
tin, and bone sialoprotein (BSP). Osteocalcin and bone
sialoprotein are considered the most sensitive markers
of bone-specific tissue formation.34–39
To engineer new bone tissue, a porous scaffold is
needed to guide cell attachment, migration, prolifera-
tion, differentiated function, and tissue regeneration
in three dimensions. Synthetic aliphatic polyesters
such as PLA, PGA, and their copolymers are biocom-
patible and biodegradable, satisfy the basic scaffold-
ing material requirements,13,14 and have been ap-
Figure 5. Osteoblast–PLLA/HAP constructs after 8 weeks
of in vitro culture (von Kossa’s silver nitrate staining): (a)
overall cross-section, original magnification ×40; (b) surface
area, original magnification ×100.
Figure 6. Northern blot analysis of the mRNA from
MC3T3-E1 subclone 4 cells cultured on PLLA and PLLA/
HAP scaffolds at varying in vitro culture times: 10 mg total
RNA from each group was used for Northern blot hybrid-
ization using cDNA probes to bone sialoprotein (BSP) and
osteocalcin (OCN).
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proved by the Federal Food and Drug Administration
(FDA) for certain human clinical applications such as
surgical sutures and some implantable devices. There-
fore, these polymers have been widely explored for
tissue engineering applications. They have been pro-
cessed into woven or nonwoven fabrics to engineer a
variety of tissues such as cartilage, tendon, heart
valves, and blood vessels.13,23,40–49 They have also
been processed into foams with a well-documented
salt-leaching technique to engineer bone, liver, and
other tissues.12,14,18,19,50–52 In addition, they have been
processed into foam structures with thermally in-
duced phase separation or emulsion-freeze-drying
techniques as tissue engineering or controlled-release
matrices.20,24,53–59
One of the disadvantages of these materials is that
the degradation products reduce the local pH, which
may accelerate the polymer degradation rate60 and in-
duce an inflammation. In addition, the mechanical
properties of these highly porous polymer scaffolds
are weak, which is disadvantageous for structural tis-
sue engineering applications. Ishaug et al. demon-
strated that stromal osteoblasts grew on PLGA foams
but the cell penetration and tissue regeneration oc-
curred only in the surface areas.17 We hypothesized
that the incorporation of a bonelike mineral—
synthetic HAP—into a highly porous biodegradable
polymer scaffold may provide the following advan-
tages for bone tissue engineering: (a) A better environ-
ment for cell seeding, survival, growth, and differen-
tiated function was expected because of the osteocon-
ductive properties imparted by HAP; (b) the acidic
degradation by-products from polyesters might be
buffered; and (c) the mechanical properties might be
improved.20
In this work, a novel phase separation technique is
used to fabricate the scaffolds, which have moduli
about 20 times higher than those of the same porosity
made with the well-documented salt-leaching tech-
nique. The mechanical properties of the PLLA/HAP
scaffolds are further significantly improved over those
of pure PLLA scaffolds. More importantly, it has been
demonstrated that the cell survival percentage on the
PLLA/HAP scaffolds is significantly improved over
that on the pure PLLA scaffolds. Moreover, the seeded
osteoblasts are more uniformly distributed in the en-
tire PLLA/HAP scaffolds compared with the cell at-
tachment primarily in the surface area of the PLLA
scaffolds. Cells also proliferate over cultivation time in
the scaffolds, which show that the scaffolding archi-
tecture is suitable for osteoblast seeding and growth.
The cell number is always higher in the PLLA/HAP
scaffolds than in the pure PLLA scaffolds during the
entire in vitro cultivation period. The bone-specific
markers (mRNAs encoding bone sialoprotein and os-
teocalcin) are expressed in both pure PLLA scaffolds
and PLLA/HAP composite scaffolds, whereas the ex-
pression levels are higher in the PLLA/HAP scaffolds.
The new bone tissue formation is significantly en-
hanced and is more uniformly distributed in the
PLLA/HAP scaffolds in three dimensions than in the
PLLA scaffolds. These results demonstrated that HAP
imparted osteoconductivity to the scaffolds. The long-
term cell survival, growth, and highly differentiated
state in the center of the osteoblast-scaffold constructs
demonstrated the advantages of the high porosity,
which lead to high permeability for nutrients, meta-
bolic wastes, and the soluble signal molecules. The
adsorption of proteins and other biologically active
molecules to HAP is likely different from that to poly-
mers. These proteins and biologically active molecules
may mediate the interactions between the osteoblastic
cells and the scaffolds. The varied interactions from
the scaffolds to the osteoblastic cells might have re-
sulted in some of the changes in cellular behavior (os-
teoconductivity of the scaffolds).
The calcification was not highly appreciable in the
osteoblast–scaffold constructs partially because of the
interference of the HAP particles incorporated. There
were also several factors that might not be ideal for
Figure 7. Normalized values of (a) osteocalcin (OCN)
mRNA, and (b) bone sialoprotein (BSP) mRNA, using 18S
rRNA cDNA as a probe as described in Materials and Meth-
ods.
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ossification. One of them could be the cell source. Al-
though a single cell type might not be ideal for calci-
fied bone matrix formation, the in vitro cultivation of
this well-characterized osteoblastic cell line allowed
for well-controlled comparison between different
types of scaffolds without complications from mixed
cell types. The lack of blood supply in an in vitro cul-
ture was known to be a disadvantage for calcified
bone formation, but was deliberately chosen to avoid
complicating systemic factors for a more controlled
comparison of the scaffolding materials. Other pos-
sible factors include not-optimized culture medium
composition, cultivation conditions, and so forth.
However, the advantages of the highly porous poly(a-
hydroxyl acids)/HAP composite scaffolds for bone
tissue engineering have been clearly demonstrated in
this work. The studies on scaffold degradation and
acidity, protein adsorption, effects of cell types, tissue
culture conditions, in vivo implantation, host tissue re-
action, and integration are under way and will be re-
ported separately.
CONCLUSIONS
Highly porous foams fabricated with a thermally
induced phase separation technique are mechanically
strong and possess architectures suitable for osteoblast
seeding and growth. The mechanical properties of the
polymer/HAP scaffolds are significantly higher than
those of the pure polymer scaffolds. The bone-
mineral–mimicking synthetic HAP imparts osteocon-
ductivity to the polymer scaffolds. The polymer/HAP
composite scaffolds have been shown to have higher
osteoblast survival rate, more uniform cell distribution
and growth, improved new tissue formation, and en-
hanced bone specific gene expression in vitro. These
results have demonstrated that the polymer/HAP
scaffolds are superior to the pure polymer scaffolds
for osseous tissue engineering. Studies on the compos-
ite scaffold degradation behavior, pH variations, pro-
tein adsorption, and in vivo tissue formation are under
way to understand the mechanisms and explore the
potentials of these new scaffolds for clinical applica-
tion.
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